Key Manufacturers - Drug Eluting Stents Industry

The goal of regulatory clearance is to make it possible for manufacturers of drug-eluting stents to sell their products and fill a gap in the market for cardiac care. For instance, the medical company Svelte Medical received FDA certification for the DES systems SLENDER IDS fixed-wire and DIRECT RX rapid-exchange for the treatment of coronary artery disease, respectively, in December 2021 and January 2022. Both the SLENDER IDS and DIRECT RX drug-eluting stent systems are highly deliverable and offer long-term therapeutic benefit to the population of patients with coronary artery disease.

The Drug Eluting Stents Market is estimated to increase at a CAGR of 6.6% from 2022 to 2030, reaching a value of US$ 2,897.2 million in 2022.

Major Players in the Drug Eluting Stents  Industry:

1) Boston Scientific Corporation:

Boston Scientific creates medical devices that require fewer incisions or smaller openings to be placed within the body. It produces goods for blood clot angioplasty, interventional oncology, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, cardiac rhythm control, and incontinence management. American headquarters in Marlborough, Massachusetts. Established in 1979. Boston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited in 2022.

2) Medtronic, Abbott Laboratories:

Abbott manufactures and distributes branded generic medications, adult and pediatric food products, testing supplies, and diagnostic equipment. A few of the goods include pacemakers, neuromodulation devices, implanted cardioverter defibrillators, coronary stents, catheters, baby formula, adult nutritional liquids, immunoassays, molecular diagnostic platforms, and point-of-care diagnostic tools. The company's headquarters are in Abbott Park in Chicago, Illinois. Abbott Laboratories was founded in 1888. Abbott submitted a proposal of $890 million to Cardiovascular Systems. "The acquisition of CSI will add fresh, complementary breakthroughs to Abbott's market-leading vascular device portfolio," stated Lisa Earnhardt, executive vice president of Abbott's medical devices.

3) Biosensors International Group:

The company CB Cardio Holdings II Ltd works in the medical field. The business creates, produces, and sells medical equipment used in heart surgery and intensive care. Moreover, the business produces and sells cardiovascular stents. It is operationally present everywhere over the world. Built in 1989. The Biosensors International Group is based in Singapore and has activities all over the world. NVT, a TAVI company, is acquired by Blue Sail Medical and Biosensors International.

4) Cook Medical:

Developer and inventor of surgical alternatives to open surgery. The company provides ligators, snares, wire guides, balloon catheters, and vena cava filters to assist the world's healthcare systems in producing better outcomes more successfully. This combines cellular therapies, medical devices, and biologic materials. Founded in 1963. head office in Bloomington, Indiana. In 2022, CooperCompanies will acquire the Cook Medical Reproductive Health company.

5) Shandong JW Medical Systems:

The owner of a drug development business planned to study drug-eluting stents. The company's research focuses on the creation of interventional healthcare for a range of ailments, allowing doctors to treat patients successfully. Founded in 2003.

6) Amaranth Medical, Inc.:

Developer of bioresorbable coronary scaffolds that will revolutionise the practise of interventional cardiology. The firm's bioresorbable coronary scaffolds are built on polymer structure and processing technologies to progressively lose its mechanical strength, keeping the vessel functional, flexible, and free from a permanent, metal implant, allowing doctors to employ it in interventional cardiac operations. head office in Mountain View, California. created in 2005.

*Definiton:

Interventional cardiologists use drug-eluting stents (DES) as vascular prostheses to maintain and open arteriosclerotic-narrowed coronary arteries.